AF
CHRS icon

Amalgamated Financial’s Coherus Oncology CHRS Stock Holding History

Amalgamated Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$404K Buy
+31,287
New +$398K ﹤0.01% 1612

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Amalgamated Financial's CHRS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Coherus Oncology (CHRS) in Q1 2022: 31,287 shares worth $404K. The stake represents ﹤0.01% of the portfolio and ranks #1612 among its holdings.

183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Amalgamated Financial held 31,287 shares of Coherus Oncology worth $404K as of Q1 2022.
  • Coherus Oncology was a new Amalgamated Financial position in Q1 2022.
  • Coherus Oncology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1612 holding.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.